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Abstract Grb2 is an 'adaptor' protein made of one SH2 and two 
SH3 domains. The SH3 domains bind to prolinerich motifs in the 
C-terminal part of the ras exchange factor Sos. Binding of the 
Grb2 SH2 domain to phosphotyrosine motifs on receptors, or 
other adaptor proteins such as Shc, recruits this Grb21Sos com- 
plex at the plasma membrane where Sos stimulates nucleotide 
exchange on ras, then ras activates raf and leads to MAP kinase 
activation. The structure of Grb2, the precise motifs 
recognised by its SH2 and SH3 domains, the way Grb2 performs 
its function, a possible regulation of its association with Sos, and 
its ability to complex with other proteins in vivo, are discussed. 
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1. Introduction 
The Growth factor binding protein Grb2 is an 'adaptor' 
protein made of one SH2 domain flanked by two SH3 domains 
[1] (Fig. 1). The SH2 domain bind to specific phosphotyrosine 
motifs, whereas the SH3 domains bind to proline rich motifs. 
The C-terminal part of the ras exchange factor Sos contains 
several proline rich motifs and binds Grb2 with a very high 
affinity. This Grb2/Sos complex mediates ras activation in re- 
sponse to growth factors, in many different kinds of cells: fi- 
broblasts, neural cells, lymphocytes, etc. Then ras activates raf 
and starts the cascade of phosphorylations leading to MAP 
kinase activation. The precise role of Grb2 to start his pathway 
is still a matter of debate. Is it only a passive adaptor that plugs 
the associated Sos on the receptor to activate ras, or does it play 
an active role in signal transduction? Does Grb2 bind to other 
proteins than Sos and has other functions? 
The structure of complete Grb2 has been solved and Grb2 
is now the best characterised member among the growing fam- 
ily of adaptor proteins that also includes Crk or Nck [2]. 
the N-terminal SH3 domain (N-SH3) mutates a highly con- 
served proline of the ligand binding site to a leucine and de- 
creases the affinity for proline rich ligands by several orders of 
magnitude. It is a severe mutation, only 9% of the larva develop 
to adults and all of them show the 'vulvaless' phenotype. The 
E89K (GluflB8) and S90N (Ser loop B-C) mutations in the SH2 
domain are much milder, there's no lethality and only a fraction 
of the animals develop the 'vulvaless' phenotype. The E89K 
mutation has only minor effects on the affinity for phosphoty- 
rosine peptides, consistent with the structure of Grb2 SH2 
where E89 side chain points to the solvent, thus the structural 
reason for the biological effects of this mutation is not under- 
stood. The G203R mutation in the C-terminal SH3 domain 
(C-SH3) does not lead to a 'vulvaless' phenotype, it is much 
milder than the P49L mutation, suggesting that Sem-5 C-SH3 
is less important than the N-SH3 for signal transduction, most 
likely because the G203R mutant of Sem-5 is still able to inter- 
act with Sos. In Grb2, the N-SH3 binds proline rich motifs of 
Sos with a ten times higher affinity than the C-SH3 [4,5] indicat- 
ing that the N-SH3 contributes more to Sos binding than the 
C-SH3. However we should keep in mind that the P49L or the 
G203R mutations greatly decrease the affinity of the corre- 
sponding SH3s for proline rich peptides but may not impair all 
the interactions with the Sos C-terminal (see last paragraph on 
the complete Grb2 structure). 
Drk, the Drosophila homologue of Grb2 makes a complex 
with Sos [6,7] and Sos is implicated in signal transduction 
downstream of several tyrosine kinase receptors: the 'sevenless' 
receptor (Sos stands for Son Of Sevenless, [8]), the Drosophila 
EGF receptor [9] and Torso (homologous to the PDGF recep- 
tor) [10]. As in the nematode, homozygotes for loss of function 
alleles of Drk die at a larval stage. Two mutants that disrupt 
signalling downstream of the Sevenless receptor tyrosine kinase 
have been isolated. The R67H (Arg ~A2), and H106Y (His 
flD4) mutations in the SH2 domain are both affecting directly 
the phosphotyrosine binding site. 
2. Function of Grb2 homologs in nematodes and Drosophila 3. The Grb21Sos complex in signal transduction 
Sem-5, the Grb2 homolog from C. elegans, was discovered 
as a gene involved upstream of ras in the Let-23 receptor tyro- 
sine kinase signalling pathway that controls vulval development 
and sex myoblast migration. Several mutants of the SH2 and 
SH3 domains have been isolated. Loss of function mutants lead 
to high mortality at the larval stage [3]. The P49L mutation in 
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Since the initial discovery that the Grb2/Sos complex medi- 
ates signal transduction from the EGF receptor to ras, in fi- 
broblasts [11 15], this Grb2/Sos complex has been implicated 
in signal transduction from many other receptor tyrosine ki- 
nases in several cell types. The interaction of Grb2 with the 
insulin receptor involves an additional adaptor: the Shc protein, 
that also binds Grb2 in a tyrosine phosphorylation dependent 
manner [16,17]. In myeloid cells too, Shc seems to be important 
in coupling Grb2/Sos to the M-CSF receptor [18]. A wide vari- 
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Fig. 1. Grb2 sequence with secondary structure lements. Regions offl-sheet (arrows) and ct-helix are indicated below the sequence. SH3 and SH2 
domains of Grb2 are connected by linkers (plain line: KPHP sequence for the first and EQVPQQP for the second). This second linker is part of an 
extended segment (LRDIEQVP) with fl strand geometry which continues in strand ffa (QPTYVQAL) of the C-terminal SH3. 
ety of stimuli induce tyrosine phosphorylation of Shc, that 
seems to be mediating ras activation in many cell types. The 
protein tyrosine phosphatase PTP1D may also be used as an 
additional adaptor, for instance it is involved in bridging the 
Grb2/Sos complex to the PDGF receptor [19]. The same role 
is postulated for its homologue Corkscrew and the Torso recep- 
tor, in Drosophila [10]. Grb2 can also bind to focal adhesion 
kinase (FAK) when FAK is phosphorylated in response to 
integrin receptors clustering on extracellular matrix [20], to the 
receptor protein-tyrosine phosphatase ~ [21], and to the chim- 
eric oncogene BCR-Abl in human leukemias with a philadel- 
phia chromosome [22]. The involvement of this Grb2/Sos com- 
plex in signal transduction i T-cells has been reviewed recently 
[23]. An alternative splice of Grb2 transcripts leads to the Grb3- 
3 variant, with a deletion in the SH2 domain, that behaves as 
a dominant negative protein, suppressing proliferative signals 
[24]. In NRK cells, EGF or PDGF induce cell division but also 
actin stress fibers disassembly and membrane ruffles formation 
(controlled by the small G proteins rho and rac, respectively). 
Antibodies against Grb2 block both responses, uggesting that 
Grb2 could also play a role in the activation of small G proteins 
of the rho/rac family [25]. 
4. Properties of Grb2 SH2 domains 
The SH2 domain of Grb2, as other SH2s [26], is made of a 
central antiparallel,8-sheet flanked by two helices (Fig. 2). The 
binding site is made of one phosphotyrosine binding pocket 
conserved in all SH2s (Grb2 R67, R86, $88, $90, H107, K109) 
and a binding surface for the 3 or 4 residues following this 
phosphotyrosine that are responsible for the specificity of each 
SH2 (Q105, F107, H108, L120, W121, Y134, L148). A nice 
alignment of SH2 domains can be found in [27]. The pioneering 
work of Songyang et al. [28,29] enabled to define the precise 
phosphotyrosine motifs recognised by specific SH2 domains. 
Grb2 SH2 was shown to recognise a YxNx motif. Optimal 
motifs with a YVNV sequence bind Grb2 SH2 with high affin- 
ities (Kd = 10-100 nM). The presence of a lysine at position +4 
decreases the affinity by a factor of 2-4 and lowers the trypto- 
phan fluorescence signal, indicating that position +4 may also 
be involved in the binding to Grb2 SH2 [4]. In Grb2 the prefer- 
ence for asparagine +2 is mainly determined by tryptophan 121 
(TrpEF1) [30]. Surprisingly, in the structure of unliganded 
Grb2 SH2 this tryptophan sits in the ligand binding cleft in a 
position where it is expected to interfere with binding (Fig. 2) 
[31], we have to wait for the structure of the SH2-Phosphoty- 
rosine peptide complex to see how the position of this trypto- 
phan is affected by ligand binding. Fluorescence experiments 
indicate that it moves to a more hydrophobic environment 
when the ligand is there [4]. Recent results (Cussac et al., in 
preparation) suggest that the requirement for an asparagine at 
position +2 is not as strict as previously expected. Nevertheless, 
the highest affinity binding motifs found so far on Shc, the EGF 
or HGF receptors, PTP1D, or the BCR-Abl fusion protein, all 
have a Y(V/E/Q/I) N (V/Q) sequence. 
5. Properties of Grb2 SH3 domains 
Each SH3 domain of Grb2 forms a ,8 barrel, as previously 
described for other SH3s (Fig. 3). Ren et al., were the first to 
show that at least some SH3 domains bind to short proline rich 
motifs [32]. Since genetic studies in Nematodes and Drosophila 
had shown that Grb2 and Sos were located between tyrosine 
kinase receptors and ras, this result prompted several groups 
to show that the SH3 domains of Grb2 bind proline rich motifs 
in the Sos C-terminal [12-15]. A short motif of Sos 
(VPVPPPVPPRRRP) is sufficient o bind Grb2 [14] and bind- 
ing can still be detected with shorter proline rich peptides (such 
as PPPVPPR) which adopt a Polyproline II helix conformation 
[33]. The highest affinity found so far for a proline rich peptide 
binding on Grb2 N-SH3 is in the micromolar ange [4]. The 
arginine seems to be essential since substitution of a lysine for 
this arginine in the EVPVPPPVPPR___peptide greatly reduces its 
binding on Grb2 [15]. We have observed that the presence of 
a second arginine at the C-terminal end of the proline-rich 
peptide (PVPPPVPPRR) increases the affinity for Grb2 and 
gives a two times higher tryptophan fluorescence signal, sug- 
gesting that the arginines come close to the conserved trypto- 
phan of the SH3 domain [4]. However, the NMR structure of 
the isolated Grb2 N-SH3 shows that the second arginine does 
not bind to the SH3 [34,35], it seems to help this region of the 
peptide to adopt a helical conformation that places the first 
arginine in an appropriate position (Fig. 3). In the crystal struc- 
ture of the Sem-5 C-SH3 [36] the aliphatic portion of the first 
arginine packs against he side chain of the conserved trypto- 
phan (explaining the tryptophan fluorescence increase ob- 
served upon ligand binding) and the guanidino group makes 
a salt bridge with a conserved carboxylic acid (El6 in Grb2 
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Fig. 2. Structure of Grb2 $H2 domain. The SH2 surface is visualised with the Grasp program [53]. The positively charged pocket which binds the 
phosphotyrosine (indigo) appears in blue in the front. The peptide is represented in green. Its position is deduced from the structure of the Syp 
SH2-peptide complex [27] and is only indicative. In this conformation the binding of the peptide would be impaired by tryptophan 121, which is found 
in the middle of the ligand binding cleft (top), in the structure of unliganded Grb2 SH2. 
Fig. 3. Structure of Grb2 N-SH3 domain. The VPPPVPPRR peptide is represented in indigo. The N-terminal proline (P2) is close to tyrosines 7and 
52 on the left, the valine in the 'box' constituted by tyrosine 52, phenylalanine 9 and tryptophan 36 appears in the middle, the conserved arginine 
which packs against ryptophan 36 and participates in electrostatic interactions with glutamic acid 16 and aspartate 33 is on the right. Reproduced 
from Goudreau et al. [34]. 
Fig. 4. Structure of complete Grb2. Ribbon diagram produced with the Molscript [54] and Raster3D [55] showing the secondary structure and relative 
orientation of the SH2 (green), N-SH3 (white) and C-SH3 (indigo) domains. Linkers are indicated in the same color as the SH2 (green). Peptide ligands 
are indicated as red ribbons with an arrow at the C-terminal end. These peptides have been modeled from the structures of the individual SH3-1igand 
complexes [34-36] or SH2-1igand complexes [26,27] and have been added only to indicate the orientation of the binding sites. 
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N-SH3, E174 in Grb2 C-SH3). This extremity of the binding 
site is flanked by two negatively charged loops: D14, D15, El6 
on one side and E30, E31, D33 on the other side, in the N- 
terminal SH3. Mutation of the first acidic cluster in the C- 
terminal SH3 (corresponding to D14, D15, El6 in the N-ter 
SH3) greatly decreases ligand binding [36]. The acidic cluster 
around positions 30, 31, 33 of the N-ter SH3 is the most mobile 
loop of the structure. Surprisingly, it was found that the SH3 
domains of Grb2 bind proline rich peptides in the opposite 
orientation than Abl, PI3Kinase and Fyn [34-36]. This is made 
possible by the pseudo-symetry of the polyproline II helix. The 
ligands of the PI3Kinase and Fyn SH3 domains contain an 
arginine at the N-terminal end, whereas an arginine is present 
at the C-terminal of Grb2 SH3 ligands. Thus the N-terminal or 
C-terminal localisation of a positively charged residue seems to 
be critical to determine the orientation of the ligand, however 
the other non-proline residues of the ligand also determine the 
affinity by interacting with specific SH3 residues [37]. For in- 
stance the valine of the PPPVPPR motif packs against W191 
and Y207 of Sem-5 C-SH3 (W36 and Y52 in Grb2 N-SH3, 
W193 and Y209 in Grb2 C-SH3). 
6. Partners of Grb2 SH3 domains 
Grb2 and the Sos C-terminal bind with high affinity and 
make a very stable complex. However several other proteins 
can bind to the SH3 domains of Grb2: Abl [38], dynamin [39], 
synapsin [40], 5-Lipoxygenase [41] and Shc (D. Cussac, unpub- 
lished). The interaction between SH3 domains and the proline 
rich tail of dynamin is rather promiscuous: the SH3 domains 
of PLC?', p85, Src and Fgr also bind dynamin [39]. Further- 
more, a wide range of proteins containing at least one proline 
rich motif are able to bind on several GST-SH3 fusions coupled 
to beads. This kind of experiment strongly suggests that the 
interaction with an SH3 may play an important role in the 
function of the protein, but do not characterise which SH3 is 
the physiologically significant partner. Since SH3 domains ap- 
pear as rather 'sticky', other functional arguments are needed 
to sort-out he physiologically relevant interactions. 
In the absence of strong experimental data there is still a 
controversy about the amount of Grb2 relative to Sos in the 
cell. The rat homolog of Grb2 was cloned independently and 
named Ash for Abundant Src Homology protein (6 clones out 
of 105 in a rat cDNA library [42]) whereas Sos seems to be 
present at lower levels (less than 1 clone out of 105 in several 
human cDNA libraries [12]). This is a rough estimation, but our 
experience with anti Grb2 and anti Sos antibodies leads us to 
similar estimations: at least 3-10 times more Grb2 than Sos, in 
fibroblasts. This Grb2/Sos ratio could change in different cell 
types, for instance high levels of Grb2 are found in neural cells 
[45]. If only a fraction of the Grb2 pool is complexed to Sos, 
the remaining Grb2 would be free to bind other proline rich 
proteins uch as dynamin or synapsins. These proteins could 
represent storage compartments for Grb2 or their interaction 
with Grb2 could play an active role. For instance, the interac- 
tion of SH3 domains with dynamin could be involved in the 
internalisation f growth factor receptors, that rapidly follows 
activation, as a down-regulation mechanism [43]. However, a 
pool of free Grb2 that would be able to complex phosphoty- 
rosine motifs through its SH2 domain but would not lead to ras 
activation is expected to behave as a dominant negative in this 
transduction pathway. And indeed, it has been observed that 
excess Grb2 can inhibit signalling to ras [44]. Nevertheless, 
NIH/3T3 cells expressing 20-30 fold higher levels of Grb2 show 
higher levels of ras activation in response to EGF than control 
NIH/3T3 [45] and similar results have been found in HER14 
cells overexpressing the EGF receptor [46]. So, the effects of 
Grb2 overexpression seem to depend on the cell type, but it is 
likely that the release of free Grb2 has to be tightly controlled. 
Cell compartmentation could explain this paradox: the pool of 
Grb2 complexed to other proteins than Sos may not have 
access to the receptors whereas only the Grb2/Sos complex 
would be in a favorable position in close proximity of the 
receptors. When a GST-Grb2 fusion protein is microinjected 
into the cytoplasm of REF-52 fibroblasts, most of it goes to 
membrane ruffles (where ras proteins are also preferentially 
localised) and this localisation requires the integrity of both 
SH3 domains [47]. However the precise localisation of en- 
dogenous Grb2 has still to be determined. 
Recent experiments suggest hat the amount of Sos bound 
to Grb2 may be modulated. For instance T-cell stimulation 
transiently increases the amount of Sos that can be co-im- 
munoprecipitated with Grb2 and this correlates with tyrosine 
phosphorylation f Shc [48]. In 3T3-L1 adipocytes the amount 
of Grb2 that can be co-immunoprecipitated with Sos decreases 
upon prolonged insulin treatment [49]. Activated MAP kinase 
is able to phosphorylate Sos on serine/threonines, mostly in its 
C-terminal part, presumably as a feedback mechanism [50]. The 
consensus phosphorylation sites do not overlap with the proline 
rich motifs and phosphorylation f the Sos C-terminus does not 
impair its binding on Grb2 in-vitro, however it correlates with 
a decrease in the amount of Grb2 bound to Sos in vivo [49,51]. 
Still, the mechanisms that regulate Grb2/Sos association are 
not precisely understood. 
7. Structure of complete Grb2 
Grb2 is a small protein of 217 a.a. (25 kDa), its structure has 
recently been solved [31]. It shows two parts (Fig. 4), the SH2 
on one side and the two contiguous SH3s on the other. The SH2 
is separated from the SH3s by two long flexible arms (or link- 
ers) the structure of the SH2 not being affected by the adjacent 
SH3s. Consistent with the observations that the isolated SH2 
has exactly the same biochemical properties than when present 
on complete Grb2, and that the binding of a phosphotyrosine 
ligand on the SH2 does not affect the binding of proline rich 
ligands on the SH3s and conversely [4]. The two SH3s make 
contacts and may not be totally independent. Each SH3 of 
Grb2 probably binds proline rich motifs following the general 
rules defined for SH3-polyproline II helix interactions [37], the 
two adjacent SH3s interacting with adjacent sites in the Sos 
C-terminal, however the two proteins could make several addi- 
tional contacts explaining the specificity and the high stability 
of this Grb2/Sos complex. Alternatively, the rather weak inter- 
action between the two SH3 domains, and the flexibility of the 
spacers linking the SH3s to the SH2 could enable the SH3s to 
dissociate and recognize multiple targets with diversely spaced 
proline rich motifs [31]. Interestingly, it has been shown that 
Grb2 can interact with the SH3-SH2-SH3 containing protein 
Vav through dimerization of the Vav N-SH3 and Grb2 C-SH3 
domains [52], suggesting that Vav N-SH3 could substitute to 
Grb2 N-SH3 for binding to Grb2 C-SH3. However most of the 
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Grb2 N-SH3 residues making contacts with the C-SH3 (E30, 
C32, D33, Y37, K50, N51, I53, E54, M55) are not conserved 
in Vav N-SH3, thus the interaction between Vav N-SH3 and 
Grb2 C-SH3 may involve different regions. 
Grb2 crystallises as a dimer, the two molecules being related 
by a local twofold axis, the SH2 of one molecule contacting the 
C-SH3 of the other and conversely. The interface between the 
two molecules in the dimer (4100 ~2) is large, suggesting a
possible physiological significance. This dimer can also be ob- 
served in solution, at high concentrations of Grb2 (> 10 mg/ml), 
but at lower concentrations Grb2 behaves as a monomer. In the 
dimer, the binding sites on the two SH2s and the four SH3s are 
accessible [31]. Since four motifs of the Sos C-terminal are good 
SH3 ligands it is tempting to speculate that a Grb2 dimer could 
bind a single Sos molecule. However a detailed understanding 
of the Grb2/Sos C-terminal interaction awaits crystallisation of
this complex. 
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